About Satellos Bioscience
Satellos Bioscience is a company based in Toronto (Canada) founded in 2012 by Michael Rudnicki and Frank Gleeson. Satellos Bioscience has raised $26.12 million across 3 funding rounds from investors including Parent Project Muscular Dystrophy. The company has 14 employees. Satellos Bioscience offers products and services including SAT-3247. Satellos Bioscience operates in a competitive market with competitors including AskBio, Cytokinetics, BioAge Labs, Solid Biosciences and Kate Therapeutics, among others.
- Headquarter Toronto, Canada
- Employees 14
- Founders Michael Rudnicki, Frank Gleeson
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website satellos.com
- Social LinkedIn X Instagram
- Legal Name Satellos Bioscience
- Net Profit-$25.38 M (USD)-23.69as on Dec 31, 2025
- EBITDA-$26.99 M (USD)-33.02as on Dec 31, 2025
- Total Equity Funding$26.12M (USD)
in 3 rounds
- Latest Funding Round$25.02M (USD), Series A
Dec 2024
- Investors
- Employee Count14
Products & Services of Satellos Bioscience
Satellos Bioscience offers a comprehensive portfolio of products and services, including SAT-3247.
Small molecule to support muscle regeneration in Duchenne muscular dystrophy.
Funding Insights of Satellos Bioscience
Satellos Bioscience has successfully raised a total of $26.12M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $25.02 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $26.12M
- Total Rounds 3
- Last Round Series A — $25.02M
- First Round $1M
(Jan 2021)
- Investors Count 1
All 3 funding rounds of Satellos Bioscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $25.02M | Series A | – | – | – |
| Sep 2022 | $99,161 | Seed | – | – | – |
| Jan 2021 | $1M | Seed | – | Parent Project Muscular Dystrophy | – |
1 investors in total: 1 institutional.
Investors in Satellos Bioscience
Satellos Bioscience has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Parent Project Muscular Dystrophy.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Foundation funding is provided to combat muscular dystrophy. | 1994 | parentprojectmd.org | Hackensack, United States |
Investor details for Satellos Bioscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Satellos Bioscience
9 people are tracked at Satellos Bioscience (9 in leadership); the tracked headcount is 14.
| Name | Role | Group |
|---|---|---|
Michael Rudnicki | Co-Founder | Leadership |
Frank Gleeson | Co-Founder & CEO | Leadership |
Philip Lambert | Chief Scientific Officer | Leadership |
William McVicar | Director | Leadership |
Deepah Singh | Vice President, Finance & Administration | Leadership |
Ryan Mitchell | Senior Vice President, Medical And Scientific Affairs | Leadership |
Elizabeth Williams | Chief Financial Officer | Leadership |
Rob Hall | Director Financial And Contracts Specialist | Leadership |
Desiree Chan | Chief Of Staff | Leadership |
Complete people profiles for Satellos Bioscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Satellos Bioscience
Satellos Bioscience is a publicly listed company on the TSX with ticker symbol MSCL in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Feb 2024
- Listed onTSX: MSCL
- Listed entitySatellos Bioscience Inc
- Exchange sectorHealth technology
Timeline of Satellos Bioscience
4 dated milestones of Satellos Bioscience across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Satellos Bioscience is founded.
- Funding First funding round of $1.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Series A, of $25.0M.
Competitors of Satellos Bioscience
Satellos Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AskBio, Cytokinetics, BioAge Labs, Solid Biosciences and Kate Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| askbio.com | 2001 | Durham, United States | $235M | – | Gene and protein therapies are developed for treating various diseases. | |
| cytokinetics.com | 1997 | San Francisco, United States | $60M | 423 | Muscle activators are developed for debilitating diseases. | |
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. | |
| solidbio.com | 2014 | Cambridge, United States | $92.5M | 101 | Gene therapy platform for Duchenne muscular dystrophy is developed. | |
| katetherapeutics.com | 2020 | San Diego, United States | $123.78M | 46 | AAV-based gene therapies for muscle diseases are developed. | |
| epirium.com | 2008 | San Diego, United States | $85M | – | Therapeutic solutions for cancer via mitochondrial biogenesis are developed. | |
| gennao.com | 2020 | Hopewell, United States | $26M | – | Developer of nucleic acid therapeutics for cancer and rare muscular disorders | |
| biophytis.com | 2006 | Romainville, France | $2.6M | – | Drugs for neuromuscular and age-related diseases are developed. | |
| vectorytx.com | 2020 | Amsterdam, Netherlands | $175.55M | – | Developer of therapeutics for neurodegenerative and muscular disorder | |
| angitiabio.com | 2018 | Woodland Hills, United States | $276M | – | Drugs for muscle, bone, and joint diseases are developed. |
Detailed competitors of Satellos Bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Satellos Bioscience
The website of Satellos Bioscience (satellos.com) receives about 6.3K visits a month.
- Monthly visits6.3K
▼ 49.5% vs previous month
Latest news on Satellos Bioscience
Complete news archive for Satellos Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Satellos Bioscience
10 companies that operate in the same segment as Satellos Bioscience (Orthopedics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Prosthetic and orthotic devices are developed for individuals with disabilities. | 1919 | Duderstadt, Lower Saxony, Germany | USD 17 M | USD 1.97 B | – | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of drugs for treating rare and autoimmune diseases | 2008 | Dublin, Ireland | USD 61.78 M | USD 617.41 M | – | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Robotic arms are provided for mobility and rehabilitation support. | 2004 | Boston, Massachusetts, United States | USD 17.21 M | USD 40.93 M | 185 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608 M | – | – | |
Exoskeletons for medical rehabilitation and industrial productivity are provided. | 2005 | United States | USD 24.37 M | USD 71.6 M | 61 | |
Stabilization devices for healthcare are manufactured by the company. | 2005 | New York, New York, United States | USD 142.15 M | – | 43 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Satellos Bioscience
Satellos Bioscience was founded in 2012 and raised its 1st funding round 9 years after it was founded.
Satellos Bioscience is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Frank Gleeson is the current CEO of Satellos Bioscience. They have also founded this company.
Satellos Bioscience is a funded company, having raised a total of $26.12M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Jan 2021.
Satellos Bioscience has 14 employees.
Satellos Bioscience was founded in 2012 in Toronto, Canada, within the biotechnology sector. Focus is placed on developing small molecule therapeutics for rare degenerative conditions, including Duchenne muscular dystrophy. Operations center on restoring muscle stem cell division and progenitor cell production. The companys lead program addresses genetic muscular disorders through targeted drug mechanisms.
Satellos Bioscience's top competitors include AskBio, Solid Biosciences and BioAge Labs.
Satellos Bioscience offers SAT-3247.
Yes, Satellos Bioscience is publicly traded on TSX under the ticker symbol MSCL.
Satellos Bioscience has 1 investor. Key investors include Parent Project Muscular Dystrophy.
Satellos Bioscience operates through Satellos Bioscience.